



RECEIVED  
FEB 28 2002  
TECH CENTER 1600/2900

# INFORMATION DISCLOSURE STATEMENT

(37 CFR 1.56, 1.97, and 1.98)

SHEET 1 OF 1

ATTORNEY DOCKET

25352-0029

APPLICATION NO.

09/977,859

APPLICANT(S)

Prasad V.V.S.V. Manchem, et al.

FILING DATE

October 11, 2001

GROUP

1824

## U.S. PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
MS	1	5,830,918	11/1998	Sportsman, et al.	514/648	
	2	5,851,988	12/1998	Sportsman, et al.	514/4	
	3	6,020,374	02/2000	Geier, et al.	514/553	
MS	4	6,051,597	04/2000	Zhang, et al.	514/414	

## FOREIGN PATENT DOCUMENTS

† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
MS	5	99/51225 ✓	10/1999	WO	
	6	01/12591 ✓	02/2001	WO	
	7	00/71506 ✓	11/2000	WO	
MS	8	91/03226 ✓	03/1991	WO	

## OTHER DOCUMENTS

† EX'R INITIAL	* REF. #	CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)
MS	9	Carr et al., "Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance", <i>Lancet</i> , <b>352</b> , 1881-1883 (1998).
	10	Carr et al., "A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors", <i>AIDS</i> , <b>12</b> , F51-F58 (1998).
	11	Roth et al., "Development of Cervical Fat Pads Following Therapy With Human Immunodeficiency Virus Type 1 Protease Inhibitors", <i>Clin. J. Infect. Dis.</i> , <b>27</b> , 65-67 (1998).
	12	Safrin et al., "Fat distribution and metabolic changes in patients with HIV infection", <i>AIDS</i> , <b>13</b> , 2493-2505 (1999).
	13	Carr et al., "Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study", <i>Lancet</i> , <b>353</b> , 2093-2099 (1999).
	14	Behrens et al., "Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors", <i>AIDS</i> , <b>13</b> , F63-F70 (1999).
	15	Reaven, "Role of insulin resistance in human disease (Syndrome X): an expanded definition", <i>Annu. Rev. Med.</i> , <b>44</b> , 121-131 (1993).
MS	16	Murata et al., "The mechanism of insulin resistance caused by HIV protease inhibitor therapy", <i>J. Biol. Chem.</i> , <b>27</b> , 20251-20254 (2000).

EXAMINER'S SIGNATURE

DATE CONSIDERED

11/26/02

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.

\* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).